Covid-19 news: Pfizer trial finds booster vaccine over 95% effective

The latest coronavirus news updated every day including coronavirus cases, the latest news, features and interviews from New Scientist and essential information about the covid-19 pandemic
Source: New Scientist - Health - Category: Consumer Health News Source Type: research

Related Links:

Clin Ther. 2021 Nov 16:S0149-2918(21)00457-4. doi: 10.1016/j.clinthera.2021.11.003. Online ahead of print.ABSTRACTPURPOSE: The goal of this study was to assess if caregivers' attitudes toward the regulatory process of approving the vaccine against coronavirus disease 2019 (COVID-19) for children aged
Source: Clinical Therapeutics - Category: Drugs & Pharmacology Authors: Source Type: research
Curr Res Pharmacol Drug Discov. 2021;2:100062. doi: 10.1016/j.crphar.2021.100062. Epub 2021 Oct 5.ABSTRACTCOVID-19 is an infectious disease that affects the respiratory system and is caused by the novel coronavirus SARS-CoV-2. It was first reported in Wuhan, China, on December 31, 2019, and has affected the entire world. This pandemic has caused serious health, economic and social problems. In this situation, the only solution to combat COVID-19 is to accelerate the development of antiviral drugs and vaccines to mitigate the virus and develop better antiviral methods and excellent diagnostic and prevention techniques. With...
Source: Cancer Control - Category: Cancer & Oncology Authors: Source Type: research
Prof Dame Sarah Gilbert says this will not be the last time a virus threatens our lives and our livelihoodsCoronavirus – latest updatesSee all our coronavirus coverageThe coronavirus pandemic that has so far killed more than 5 million people worldwide is far from over and the next one could be even more lethal, the creator of the Oxford/AstraZeneca vaccine has said.As fears grow over the threat posed by the highly mutated Omicron variant, detected in more than 30 countries,Prof Dame Sarah Gilbert cautioned that while it was increasingly obvious that “this pandemic is not done with us”, the next one could ...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Coronavirus UK news World news Science Infectious diseases Source Type: news
Millions of people have died of COVID-19 since the pandemic began. During the past two years, many drug and vaccine studies have been conducted against the novel type of coronavirus. However, at the time of this writing, there are still serious questions about the prophylaxis and pharmacotherapy options, and unfortunately the deaths continue to climb.
Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology - Category: OBGYN Authors: Source Type: research
The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global health concern. The development of vaccines with high immunogenicity and safety is crucial for controlling the global COVID-19 pandemic and preventing further illness and fatalities. Here, we report the development of a SARS-CoV-2 vaccine candidate, Nanocovax, based on recombinant protein production of the extracellular (soluble) portion of the spike (S) protein of SARS-CoV-2. The results showed that Nanocovax induced high levels of S protein-specific IgG and neutralizing antibodie...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
NEW BRUNSWICK, N.J., DECEMBER 5, 2021 – Johnson &Johnson (NYSE: JNJ) (the Company) today announced preliminary results from an independent study, including a subset of participants from the Janssen-sponsored COV2008 study, conducted by Dan Barouch, M.D., Ph.D., et al. of Beth Israel Deaconess Medical Center (BIDMC), which showed that a booster shot of the Johnson &Johnson COVID-19 vaccine (Ad26.COV2.S), administered at six months after a two-dose primary regimen of BNT162b2, increased both antibody and T-cell responses. These results demonstrate the potential benefits of heterologous boosting (mix-and-match)....
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Brief Bioinform. 2021 Dec 2:bbab485. doi: 10.1093/bib/bbab485. Online ahead of print.ABSTRACTThe coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), rapidly became a global health challenge, leading to unprecedented social and economic consequences. The mechanisms behind the pathogenesis of SARS-CoV-2 are both unique and complex. Omics-scale studies are emerging rapidly and offer a tremendous potential to unravel the puzzle of SARS-CoV-2 pathobiology, as well as moving forward with diagnostics, potential drug targets, risk stratification, therapeutic res...
Source: Briefings in Bioinformatics - Category: Bioinformatics Authors: Source Type: research
CONCLUSIONS: An effective pandemic response requires comprehensive institutional preparedness that facilitates flexibility and surge capacity. The single most important action leaders of medical research organizations can take to prepare for the next pandemic is to develop a quick-reaction force that would activate under prespecified criteria to manage reprioritization of all science and support activities to address pandemic response priorities at the velocity of relevance.PMID:34865097 | DOI:10.1093/milmed/usab438
Source: Military Medicine - Category: International Medicine & Public Health Authors: Source Type: research
J Virol Methods. 2021 Dec 1:114398. doi: 10.1016/j.jviromet.2021.114398. Online ahead of print.ABSTRACTCoronavirus disease 2019 (COVID-19) vaccination programs rolled out in an attempt to stop the COVID-19 pandemic. Besides neutralising antibodies, effective T cell responses are also crucial for protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19 disease severity. To assess SARS-CoV-2-specific T cell immunity, we developed an interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISpot) that can be deployed in research and diagnostic settings. We optimised our ELISpot ...
Source: Journal of Virological Methods - Category: Virology Authors: Source Type: research
Vaccine. 2021 Nov 19:S0264-410X(21)01467-5. doi: 10.1016/j.vaccine.2021.11.023. Online ahead of print.ABSTRACTFrance is one of the most vaccine-hesitant countries in the world, including for coronavirus disease 2019 (COVID-19). After 10 months of restrictive measures and media coverage of the dangers of COVID-19, French attitudes towards a vaccine continue to deteriorate. The communication strategies of the government have not helped; in fact, they have made the situation worse. Empirical studies on the national strategy for management of the COVID-19 pandemic in France have shed light on the reasons for vaccine hesitancy....
Source: Vaccine - Category: Allergy & Immunology Authors: Source Type: research
More News: Coronavirus | COVID-19 | Health | Pandemics | Pfizer | Vaccines